BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines-Reference-Cited by-同舟云学术

BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines

Published:2008-06-01 Issue:6 Volume:93 Page:2194-2201
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Leboeuf Rebecca¹,Baumgartner Jacqueline E.¹,Benezra Miriam¹,Malaguarnera Roberta¹,Solit David²¹,Pratilas Christine A.³,Rosen Neal⁴¹,Knauf Jeffrey A.¹,Fagin James A.²¹

Affiliation:

1. Departments of Medicine (R.L., J.E.B., M.B., R.M., D.S., N.R., J.A.K., J.A.F.), Memorial Sloan Kettering Cancer Center, New York, New York 10021

2. Department of Human Oncology and Pathogenesis Programs (D.S., J.A.F.), Memorial Sloan Kettering Cancer Center, New York, New York 10021

3. Department of Pediatrics (C.A.P.), Memorial Sloan Kettering Cancer Center, New York, New York 10021

4. Department of Molecular Pharmacology (N.R.), Memorial Sloan Kettering Cancer Center, New York, New York 10021

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/93/6/2194/9056689/jcem2194.pdf

Reference32 articles.

1. Molecular mechanisms of RET activation in human cancer.;Santoro;Ann NY Acad Sci,2002

2. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.;Greco;Oncogene,1992

3. Prevalence of Ras mutations in thyroid neoplasia.;Esapa;Clin Endocrinol (Oxf),1999

4. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.;Zhu;Am J Clin Pathol,2003

5. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.;Kimura;Cancer Res,2003

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan;Thyroid®;2024-03-14

2. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial;Thyroid;2022-07-05

3. Intratumor Epigenetic Heterogeneity—A Panel Gene Methylation Study in Thyroid Cancer;Frontiers in Genetics;2021-09-03

4. New Therapies for Advanced Thyroid Cancer;Frontiers in Endocrinology;2020-05-22

5. A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis;Cancer Research;2019-09-26